Literature DB >> 25756549

Successes, challenges and developments in Australian rheumatology.

Eric F Morand1, Michelle T Leech2.   

Abstract

Australia is a geographically vast but sparsely populated country with many unique factors affecting the practice of rheumatology. With a population comprising minority Indigenous peoples, a historically European-origin majority population, and recent large-scale migration from Asia, the effect of ethnic diversity on the phenotype of rheumatic diseases such as systemic lupus erythematosus (SLE) is a constant of Australian rheumatology practice. Australia has a strong system of universal healthcare and subsidized access to medications, and clinical and research rheumatology are well developed, but inequitable access to specialist care in urban and regional centres, and the complex disconnected structure of the Australian healthcare system, can hinder the management of chronic diseases.

Entities:  

Mesh:

Year:  2015        PMID: 25756549     DOI: 10.1038/nrrheum.2015.22

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN: 1759-4790            Impact factor:   20.543


  58 in total

1.  Why aren't there more women leaders in academic medicine? the views of clinical department chairs.

Authors:  M J Yedidia; J Bickel
Journal:  Acad Med       Date:  2001-05       Impact factor: 6.893

2.  The role of economic evaluation in the pricing and reimbursement of medicines.

Authors:  M Drummond; B Jönsson; F Rutten
Journal:  Health Policy       Date:  1997-06       Impact factor: 2.980

3.  Drug prices and value for money: the Australian Pharmaceutical Benefits Scheme.

Authors:  David A Henry; Suzanne R Hill; Anthony Harris
Journal:  JAMA       Date:  2005-11-23       Impact factor: 56.272

4.  Systemic lupus erythematosus in Aborigines and Caucasians in central Australia: a comparative study.

Authors:  M Segasothy; P A Phillips
Journal:  Lupus       Date:  2001       Impact factor: 2.911

5.  Centralized drug review processes in Australia, Canada, New Zealand, and the United kingdom.

Authors:  Steven G Morgan; Meghan McMahon; Craig Mitton; Elizabeth Roughead; Ray Kirk; Panos Kanavos; Devidas Menon
Journal:  Health Aff (Millwood)       Date:  2006 Mar-Apr       Impact factor: 6.301

6.  Macrophage migration inhibitory factor deficiency attenuates macrophage recruitment, glomerulonephritis, and lethality in MRL/lpr mice.

Authors:  Alberta Y Hoi; Michael J Hickey; Pamela Hall; Jiro Yamana; Kim M O'Sullivan; Leilani L Santos; Will G James; A Richard Kitching; Eric F Morand
Journal:  J Immunol       Date:  2006-10-15       Impact factor: 5.422

Review 7.  Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality.

Authors:  Rupert W Jakes; Sang-Cheol Bae; Worawit Louthrenoo; Chi-Chiu Mok; Sandra V Navarra; Namhee Kwon
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-02       Impact factor: 4.794

8.  Systemic lupus erythematosus in the far north of Queensland.

Authors:  D Bossingham
Journal:  Lupus       Date:  2003       Impact factor: 2.911

9.  Systemic lupus erythematosus in Australian aborigines: high prevalence, morbidity and mortality.

Authors:  N M Anstey; I Bastian; H Dunckley; B J Currie
Journal:  Aust N Z J Med       Date:  1993-12

10.  Potential role of the lectin pathway of complement in the pathogenesis and disease manifestations of systemic sclerosis: a case-control and cohort study.

Authors:  Michael Osthoff; Gene-Siew Ngian; Melinda M Dean; Mandana Nikpour; Wendy Stevens; Susanna Proudman; Damon P Eisen; Joanne Sahhar
Journal:  Arthritis Res Ther       Date:  2014-11-18       Impact factor: 5.156

View more
  2 in total

1.  Patient-Reported Experience Measures in outpatient rheumatology care: a systematic review.

Authors:  Madeleine J Bryant; Jonathon P Schubert; Rachel J Black; Catherine L Hill
Journal:  Rheumatol Adv Pract       Date:  2021-10-30

2.  Association of MIF, but not type I interferon-induced chemokines, with increased disease activity in Asian patients with systemic lupus erythematosus.

Authors:  K L Connelly; R Kandane-Rathnayake; A Hoi; Mandana Nikpour; E F Morand
Journal:  Sci Rep       Date:  2016-07-25       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.